Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

NKGen Biotech, Inc. - Common Stock (NQ: NKGN )

0.2690 -0.0010 (-0.37%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NKGen Biotech, Inc. - Common Stock

< Previous 1 2 3 Next >
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Passage of the Amendment to the Advanced Regenerative Biotech Act a Positive Catalyst for Korean and Japanese Cell Therapy Companies
Via Get News
Passage of the Amendment to the Advanced Regenerative Biotech Act a Positive Catalyst for Korean and Japanese Cell Therapy Companies
--News Direct-- 
Via News Direct
Passage of the Amendment to the Advanced Regenerative Biotech Act a Positive Catalyst for Korean and Japanese Cell Therapy Companies
New York, Feb 7, 2024 - (Plato Data) - On Thursday February 2, 2024, the bio industry welcomed the parliament’s passage of a bill that adds regenerative medicine organizations to the list of those... 
Via TheNewswire.com
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting off trading on Tuesday with a look into the biggest pre-market stock movers traders need to keep an eye on today! 
Via InvestorPlace
NKGen Biotech Advances Alzheimer’s Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial
Via Get News
NKGen Biotech Advances Alzheimer's Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial
SANTA ANA, Calif., Dec. 29, 2023 - (Plato / Amplifi via 500NewsWire) -- NKGen Biotech, Inc. (Nasdaq: NKGN) is making strides in Alzheimer's disease (AD) treatment with the dosing of the first patient... 
Via TheNewswire.com
NKGen Biotech Advances Alzheimer's Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial
--News Direct-- 
Via News Direct
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Barnes Group Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Apollomics, Inc. (NASDAQ: APLM) shares surged 88.4% to $1.07 stoma multiforme with PTPRZ-MET fusion. 
Via Benzinga
Why Is PTC Therapeutics (PTCT) Stock Down 23% Today?
PTC Therapeutics stock is falling on Friday as PTCT investors react to the company's lackluster earnings report for Q3 2023. 
Via InvestorPlace
Why Is TransCode Therapeutics (RNAZ) Stock Down 25% Today?
TransCode Therapeutics stock is falling on Friday after the company announced plans for a public offering of RNAZ shares. 
Via InvestorPlace
Why Intel Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Gainers NKGen Biotech, Inc. (NASDAQ: NKGN) shares surged 60.9% to $6.08 in pre-market trading after gaining 8% on Thursday. NKGen Biotech presented Phase I clinical trial data at the 16th Annual... 
Via Benzinga
Why Is Apollomics (APLM) Stock Up 113% Today?
Apollomics stock is taking off on Friday with heavy trading of APLM following its latest study news presented to traders yesterday. 
Via InvestorPlace
Why Is NKGen Biotech (NKGN) Stock Up 18% Today?
NKGen Biotech stock is taking off on Friday as NKGN investors react to the company's clinical trial results for its Alzheimer’s treatment. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to start off the final trading day this week with a breakdown of the biggest pre-market stock movers on Friday! 
Via InvestorPlace
NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimer’s Disease Treatment.
Via Get News
Exposures Product Safety
NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimer’s Disease Treatment.
--News Direct-- 
Via News Direct
Exposures Product Safety
NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimer’s Disease Treatment.
SANTA ANA, Calif., Oct. 24, 2023 (Plato / Amplifi) -- Today, NKGen Biotech Inc. (Nasdaq: NKGN), a trailblazer in the field of autologous, allogeneic, and CAR-NK natural killer cell therapeutics,... 
Via TheNewswire.com
Exposures Product Safety
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time for another dive into the biggest pre-market stock movers as we list out the top stocks worth watching on Tuesday! 
Via InvestorPlace
Why Accolade Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Orchard Therapeutics plc (NASDAQ: ORTX) shares climbed 97.7% to $15.98 after the company agreed to be acquired by Japan's Kyowa Kirin for $16.00 per ADS in cash plus an additional contingent... 
Via Benzinga
Why Orchard Therapeutics Shares Are Trading Higher By Around 95%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are rising and falling on Thursday as we check out all of the latest news worth knowing about this morning! 
Via InvestorPlace
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.